Idec's Zevalin gets September panel date

The FDA's Oncologic Drugs Advisory Committee will review on Sept. 11 IDPH's BLA for its Zevalin ibritumomab tiuxetan radioimmunotherapy to treat relapsed or refractory, low grade, follicular, CD20-pos...